


Exploring novel leukemia therapies using the 'the complex alphabet of mRNA'

December 7 2023



Graphical Abstract. Credit: *Molecular Cell* (2023). DOI: 10.1016/j.molcel.2023.11.003

Around 320,000 new cases of leukemia, a type of blood cancer that can affect all population groups, are diagnosed every year in Europe. In children, cases of leukemia make up a third of diagnosed cancers. Chemotherapy is the primary treatment for leukemia.

Often, the exact cause cannot be identified and the molecular and cellular mechanisms responsible for leukemia remain shrouded in mystery. Therefore, discovering new detection methods and treatments to eradicate leukemia is a major challenge in oncology.

Messenger RNA has been in the news in recent months in connection with COVID-19 vaccinations. In an article [published](#) in *Molecular Cell*, researchers from the Université libre de Bruxelles (ULB) and the Bordet Institute, Brussels University Hospital (Hôpital universitaire de Bruxelles—H.U.B.) are opening another equally innovative avenue of research: novel anti-cancer therapies using the complex alphabet of messenger RNA (or RNA epigenetics).

As with DNA, along with its four well-known letters (A, U, G, C), RNA's chemical makeup also includes additional letters. This is the case for the letter m5C, or methylation of messenger RNA, which plays an essential role in [gene regulation](#) through the reading of m5C by proteins that bind to it, called "readers.", These m5C readers have still not been described in detail and their role in cancer is unknown.

The recent work of the team led by Prof. François Fuks—Director of the Laboratory of Cancer Epigenetics, ULB Faculty of Medicine and Bordet Institute H.U.B. and Director of the ULB Cancer Research

Center (U-CRC), Université libre de Bruxelles—has identified a new RNA reader, SRSF2. For the first time, it is shedding light on the SRSF2 protein's key role in the development of leukemia.

The SRSF2 gene is one of the most frequently mutated genes in leukemia cases: up to 50% in certain types of leukemia. The researchers demonstrated that the SRSF2 protein reads the m5C modification in RNA; they also highlighted a previously unsuspected molecular mechanism that can lead to leukemia: the mutation of SRSF2 alters its ability to read m5C in RNA, which inhibits its function of regulating messenger RNA.

Furthermore, by analyzing nearly 700 samples taken from leukemia patients, Prof. François Fuks and his colleagues were able to identify a new group of patients whose chances of survival are particularly low due to the reduced ability of SRSF2 to read m5C.

This research, which is part of a boom in discoveries in the field of the RNA alphabet, was published in the journal *Molecular Cell*. These discoveries should not only begin a new chapter of knowledge in our understanding of why leukemia appears but should also lead us to a new paradigm in the diagnosis and treatment of leukemia based on the epigenetics of RNA.

In concrete terms, the discoveries could lead to specific diagnoses of patients with a poor vital prognosis, in whom the "m5C reader" function of SRSF2 is affected. Moreover, a new therapeutic approach to leukemia could be envisaged by developing an inhibitor that could help SRSF2 to read m5C correctly again, as this reading ability is reduced in patients with the SRSF2 mutation.

More information: Hai-Li Ma et al, SRSF2 plays an unexpected role as reader of m5C on mRNA, linking epitranscriptomics to cancer,

Molecular Cell (2023). [DOI: 10.1016/j.molcel.2023.11.003](https://doi.org/10.1016/j.molcel.2023.11.003)

Provided by Université libre de Bruxelles

Citation: Exploring novel leukemia therapies using the 'the complex alphabet of mRNA' (2023, December 7) retrieved 27 April 2024 from <https://medicalxpress.com/news/2023-12-exploring-leukemia-therapies-complex-alphabet.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.